Director, Division of Therapeutics and Medical Consequences – NIDA/NIH
The National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH) is seeking exceptional candidates for the position of Director, Division of Therapeutics and Medical Consequences (DTMC).
The DTMC Director provides leadership and direction for an extramural scientific research program of national and international scope. This position is 1 of the 6 senior scientific positions that directly reports to and advises the NIDA Director. The primary goal of the division is to improve the treatment of substance use disorders (SUDs) through the development of new medications, devices, and behavioral therapies. Improving treatment of infectious diseases in SUD populations is another priority goal of the division. To implement these goals, the Director reviews current programs, and develops and implements new initiatives, with a staff of 27 extramural scientists and 3 administrative staff, through a process of meetings with outside advisors, requests for applications and program announcements, contract solicitations and allocation of contract resources for specific projects, collaborations with the pharmaceutical industry, scientific presentations, and publications in the peer-reviewed literature. DTMC manages a grants and contracts portfolio of over $200M per year, including one of the NIH Helping to End Addiction Long-term (HEAL) Initiative’s largest programs.
The successful candidate must possess an M.D., and/or Ph.D. degree, and have expert knowledge in the field of drug addiction and experience in the development of therapeutics for SUDs, including the design and execution of complex multi-site clinical trials. Executive level leadership and strategic planning experience is highly desirable. The successful candidate must also have demonstrated the ability to manage personnel, budgets, and timelines across multiple fiscal years.
DTMC focuses on the development of new therapies for the treatment of substance use disorders (SUDs) and related medical and psychiatric conditions. To accomplish this mission, the division a) plans and directs studies to identify, evaluate and develop new medications and devices for Food and Drug Administration (FDA) review and approval; b) develops and administers a national program of basic and clinical research to develop innovative immunological, pharmacological, and behavioral treatment approaches; c) supports training in the pre-clinical and clinical sciences; d) collaborates with the pharmaceutical industry and other federal entities to facilitate medications development for substance use disorders; e) and works closely with the FDA to assure that the research designed to demonstrate safety and efficacy is evaluated and leads to approval in the most expeditious manner.
Additionally, DTMC conducts research on the medical consequences of substance use disorders. To accomplish this mission, the division administers a national and international program on the medical consequences of licit and illicit drug use and co-occurring viral, bacterial, and fungal infections. The program has concentrated on HIV, Hepatitis C, and tuberculosis infections, with a special emphasis on co-infection of HIV and Hepatitis C infection. Other areas of programmatic emphasis are drug-drug interactions between treatment medications for substance use disorders and medications for treatment of infectious diseases in populations experiencing drug usage.
To learn more about the position, benefits, and application process, please see the full vacancy announcement at https://hr.nih.gov/jobs/search/executive/job-59831.
Position open until filled.
Applications will begin review by the search committee on September 5, 2023.
NIDA, NIH, AND HHS ARE EQUAL OPPORTUNITY EMPLOYERS
To apply for this job please visit hr.nih.gov.